<DOC>
	<DOCNO>NCT01825707</DOCNO>
	<brief_summary>The purpose study determine absorption , metabolism , excretion ( AME ) kinetics YH4808 determine characterize metabolite present plasma , urine , feces man follow single dose [ 14C ] YH4808 200 mg ( ~100 µCi ±20 µCi ) administer single oral dose .</brief_summary>
	<brief_title>AME Study 14C-YH4808 Healthy Male Subjects</brief_title>
	<detailed_description>Potential subject screen assess eligibility enter study within 28 day prior Study Entry ( ie , prior Check-in [ Day -1 ] ) . Subjects confine Clinical Research Unit ( CRU ) Check ( Day -1 ) Discharge Criteria meet ( early Day 6 late Day 11 ) . In study design , physical examination , electrocardiogram ( ECGs ) , vital sign , How feel ? ( HDYF ? ) Inquiries , clinical laboratory evaluation perform Screening , specify time study , and/or Clinic Discharge . All AEs , whether volunteer , elicit , note physical examination , record throughout study ( ie , dose Day 1 Clinic Discharge [ Day 11 ] ) .</detailed_description>
	<criteria>clinical laboratory evaluation within reference range test laboratory negative test select drug abuse , hepatitis panel HIV antibody screen able comprehend willing sign Informed Consent Form significant history clinical manifestation significant metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder history stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug participation 1 radiolabeled investigational study drug trial within 12 month prior Checkin donation blood 30 day prior Screening Study Completion , inclusive , plasma 2 week prior Screening Study Completion , inclusive</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>